Urgent.News

What's breaking now, across thousands of outlets.

Business

Celltrion Extends Biosimilar Lead Across Asia

Celltrion is solidifying its dominance in the Asian region, a representative pharmerging (emerging pharmaceutical) market, driven by the overwhelming market share of its flagship product lineup for autoimmune diseases and anticancer treatments.Celltrion announced on Nov. 19 that it is maintaining th

Celltrion is strengthening its position in Asia with its biosimilar product lineup, which includes autoimmune disease treatments and anticancer therapies. The company reported maintaining its leading market share in key Asian countries such as Malaysia, Singapore, and Thailand through an optimized direct sales strategy that caters to each country's bidding environment and medical institution demand.

According to IQVIA's pharmaceutical market research, Celltrion's flagship autoimmune disease treatment 'Remsima' held a 95% market share in Singapore, 83% in Hong Kong, and 75% in Malaysia in the second quarter of 2026. Similarly, in the oncology sector, its breast and gastric cancer treatment 'Herzuma' (trastuzumab) ranked first in Hong Kong (67%), Thailand (59%), and Malaysia (52%).

In Thailand, 'Remsima' increased its market share by 17 points, widening its lead over competing products. For blood cancer treatment, 'Truxima' (rituximab) secured a 92% market share in Singapore, 78% in Thailand, and 41% in Hong Kong. In Malaysia, the oncology treatment 'Vegzelma' (bevacizumab) climbed to first place in Q1 2026, growing its market share from 25% in Q4 2025.

Celltrion attributes its success to a local direct sales strategy that ensures stable supply and swift response to medical institutions, along with collaborating with major medical institutions and participating in academic conferences to highlight product clinical strengths. The company is also launching new, high-margin products, utilizing existing flagship product networks to accelerate market share growth.

Celltrion plans to introduce 'Vegzelma' in Hong Kong by November, 'Stoboclo' (denosumab) to Thailand in December, and 'Eydenzelt' (aflibercept) in Singapore and 'Omyqlo' in Thailand in February 2027. This success demonstrates how Celltrion's consolidated direct sales infrastructure, established as a first-generation biosimilar leader in Asia, acts as a "virtuous cycle foothold," lowering costs for future high-margin launches and maximizing profitability.

Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesskorea.co.kr →

More in Business

More from Thursday 19 November →